


Dokumentasjonsark: Nasjonal faglig retningslinje for hjerneslag

Spørsmål 2.3: Er NOAK bedre eller like gode som warfarin hos pasienter med atrieflimmer og iskemisk hjerneslag?

P	Alle med hjerneinfarkt, TIA og atrieflimmer	
I	NOAK	Dato for søk: 21.06.2016
C	Warfarin	Søk oppdatert dato:
O	Recidiv hjerneinfarkt, hjernblødning, død, andre major bleedings	Biblioteket for helseforvaltning



Tabell 1a. Inkluderte systematiske oversikter (oversiktsartikler).

Forfatter, år	Metodisk kvalitet	Egne kommentarer
Liu et al., 2014	Moderat	Uklart om det er sikret mot seleksjonsskjevhet

Tabell 2. Ekskluderte referanser. Sammendraget/tittel funnet relevant, ekskludert etter vurdering av fulltekst av artikkel.

Forfatter, år	Kommentar/begrunnelse for eksklusjon
Bajaj et al., 2016	Konferanseabstrakt
Bruins Slot & Berge, 2014	Ikke en systematisk litteraturoversikt
Chai-Adisaksopha, Hillis, Isayama, & Crowther, 2015	Konferanseabstrakt
Chai-Adisaksopha, Hillis, Isayama, Lim, et al., 2015	Møter ikke PICO grunnet studiepopulasjon
Cope, Keen, Chen, & Bergrath, 2014	Konferanseabstrakt
Dogliotti, Paolasso, & Giugliano, 2014	Møter ikke PICO grunnet studiepopulasjon
Fauchier et al., 2015	Møter ikke PICO grunnet studiepopulasjon
Fu et al., 2014	Møter ikke PICO grunnet studiepopulasjon
Garg et al., 2016	Møter ikke PICO grunnet studiepopulasjon
Gomez-Outes, Suarez-Gea, Terleira-Fernandez, Vargas-Castrillon, & Calvo-Rojas, 2015	Møter ikke PICO grunnet studiepopulasjon
Hanley & Kowey, 2015	Ikke en systematisk litteraturoversikt
Hicks, Stewart, & Eisinga, 2016	Møter ikke PICO grunnet studiepopulasjon
Jia, Lynn, Rong, & Zhang, 2014	Møter ikke PICO grunnet studiepopulasjon
Kumana, Cheung, Siu, Tse, & Lauder, 2016	Ikke en systematisk litteraturoversikt
Kundu et al., 2016	Møter ikke PICO grunnet studiepopulasjon
Lega et al., 2014	Møter PICO ved subgruppe-analyse, men ekskludert grunnet lav-

	metodisk kvalitet
Liew, O'Donnell, & Douketis, 2014	Møter ikke PICO grunnet studiepopulasjon
Lin et al., 2015	Møter ikke PICO grunnet studiepopulasjon
Lip et al., 2016	Møter PICO ved subgruppe-analyse, men ekskludert grunnet lav-metodisk kvalitet
Meyer Dos Santos & Harder, 2014	Ikke en systematisk litteraturoversikt
Romanelli, Nolting, Dolginsky, Kym, & Orrico, 2016	Møter ikke PICO grunnet studiepopulasjon
Ruff et al., 2014	Møter PICO ved subgruppe-analyse, men ekskludert grunnet lav-metodisk kvalitet
Salazar, del Aguila, & Cordova, 2014	Møter ikke PICO grunnet studiepopulasjon
Skaistis & Tagami, 2015	Møter ikke PICO grunnet studiepopulasjon
Steinberg, 2014	Ikke en systematisk litteraturoversikt
Vaz Carneiro & Costa, 2014	Ikke en systematisk litteraturoversikt

Fullstendig referanseliste (inkluderte og ekskluderte referanser).

- Bajaj, N. S., Kalra, R., Arora, G., Hashim, T., Whitfield, T., Godara, H., . . . Arora, P. (2016). Comparison of approaches for "net clinical benefit" in patients with non-valvular atrial fibrillation: A network meta-analyses of randomized control trials. *Journal of the American College of Cardiology*, *1*), 796.
- Bruins Slot, K. M. H., & Berge, E. (2014). Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation. *JAMA - Journal of the American Medical Association*, *311*(11), 1150-1151. doi:<http://dx.doi.org/10.1001/jama.2014.1403>
- Chai-Adisaksopha, C., Hillis, C., Isayama, T., & Crowther, M. (2015). Fatal bleeding, case-fatality rate of major bleeding and all-cause mortality in patients taking target-specific oral anticoagulant, a meta-analysis of randomized controlled trials. *Journal of the American College of Cardiology*, *1*), A2052.
- Chai-Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015). Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *Journal of Thrombosis and Haemostasis*, *13*(11), 2012-2020. doi:<http://dx.doi.org/10.1111/jth.13139>
- Cope, S., Keen, A., Chen, M., & Bergrath, E. (2014). Comparative efficacy of new oral anticoagulants for stroke prevention in atrial fibrillation among patients with prior stroke or systemic embolism. *Value in Health*, *17* (3), A105. doi:<http://dx.doi.org/10.1016/j.jval.2014.03.612>
- Dogliotti, A., Paolasso, E., & Giugliano, R. P. (2014). Current and new oral antithrombotics in nonvalvular atrial fibrillation: A network meta-analysis of 79 808 patients. *Heart*, *100*(5), 396-405. doi:<http://dx.doi.org/10.1136/heartjnl-2013-304347>
- Fauchier, L., Darwiche, W., Bejan Angoulvant, T., Clementy, N., Angoulvant, D., Babuty, D., & Diebart, F. (2015). Bleeding risk in patients treated with dabigatran or vitamin K antagonist for non-

- valvular atrial fibrillation : A meta analysis of matched analysis in routine care settings. *Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology*, 17, iii86.
doi:<http://dx.doi.org/10.1093/europace/euv158>
- Fu, W., Guo, H., Guo, J., Lin, K., Wang, H., Zhang, Y., . . . Shan, Z. (2014). Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. *Journal of Cardiovascular Medicine*, 15(12), 873-879.
doi:<http://dx.doi.org/10.2459/JCM.000000000000206>
- Garg, J., Chaudhary, R., Krishnamoorthy, P., Palaniswamy, C., Shah, N., Bozorgnia, B., & Natale, A. (2016). Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. *International Journal of Cardiology*, 218, 235-239.
doi:<http://dx.doi.org/10.1016/j.ijcard.2016.05.059>
- Gomez-Outes, A., Suarez-Gea, M. L., Terleira-Fernandez, A. I., Vargas-Castrillon, E., & Calvo-Rojas, G. (2015). Direct oral anticoagulants versus warfarin for stroke prevention in atrial fibrillation: A subgroup meta-analysis in European patients. *Clinical Therapeutics*, 1), e10.
- Hanley, C. M., & Kowey, P. R. (2015). Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? *Journal of Thoracic Disease*, 7(2), 165-171.
doi:<http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.23>
- Hicks, T., Stewart, F., & Eisinga, A. (2016). NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. *Open Heart*, 3(1), e000279.
doi:<http://dx.doi.org/10.1136/openhrt-2015-000279>
- Jia, B., Lynn, H. S., Rong, F., & Zhang, W. (2014). Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. *Journal of Cardiovascular Pharmacology*, 64(4), 368-374. doi:<http://dx.doi.org/10.1097/FJC.000000000000129>
- Kumana, C. R., Cheung, B. M., Siu, D. C., Tse, H. F., & Lauder, I. J. (2016). Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. *Cardiovascular Therapeutics*, 34(2), 100-106.
doi:<http://dx.doi.org/10.1111/1755-5922.12173>
- Kundu, A., Sen, P., Sardar, P., Chatterjee, S., Kapoor, A., & McManus, D. D. (2016). Intracranial hemorrhage with target specific oral anticoagulants in patients with atrial fibrillation: An updated meta-analysis of randomized controlled trials. *International Journal of Cardiology*, 203, 1000-1002. doi:<http://dx.doi.org/10.1016/j.ijcard.2015.11.097>
- Lega, J. C., Bertoletti, L., Gremillet, C., Chapelle, C., Mismetti, P., Cucherat, M., . . . Laporte, S. (2014). Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. *PLoS One*, 9(3), e91398.
doi:<http://dx.doi.org/10.1371/journal.pone.0091398>
- Liew, A., O'Donnell, M., & Douketis, J. (2014). Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials. *Journal of Thrombosis and Haemostasis*, 12(9), 1419-1424.
doi:<http://dx.doi.org/10.1111/jth.12651>
- Lin, L., Lim, W. S., Zhou, H. J., Khoo, A. L., Tan, K. T., Chew, A. P., . . . Lim, B. P. (2015). Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis. *Journal of the American Medical Association*, 313(12), 1103.e1101-1119. doi:<http://dx.doi.org/10.1016/j.jamda.2015.09.008>
- Lip, G. Y., Mitchell, S. A., Liu, X., Liu, L. Z., Phatak, H., Kachroo, S., & Batson, S. (2016). Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. *International Journal of Cardiology*, 204, 88-94.
doi:<http://dx.doi.org/10.1016/j.ijcard.2015.11.084>
- Liu, G. J., Wang, Y. F., Chen, P. Y., Chang, W., Tu, M. L., Chang, L. Y., . . . Luo, J. (2014). The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients:

- A systematic review and meta-analysis. *Drug Delivery*, 21(6), 436-452.
doi:<http://dx.doi.org/10.3109/10717544.2013.873500>
- Meyer Dos Santos, S., & Harder, S. (2014). Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. *Drug Safety*, 37(5), 295-307.
doi:<http://dx.doi.org/10.1007/s40264-014-0151-1>
- Romanelli, R. J., Nolting, L., Dolginsky, M., Kym, E., & Orrico, K. B. (2016). Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. *Circulation. Cardiovascular Quality & Outcomes*, 9(2), 126-134.
doi:<http://dx.doi.org/10.1161/CIRCOUTCOMES.115.002369>
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., . . . Antman, E. M. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*, 383(9921), 955-962. doi:[http://dx.doi.org/10.1016/S0140-6736\(13\)62343-0](http://dx.doi.org/10.1016/S0140-6736(13)62343-0)
- Salazar, C. A., del Aguila, D., & Cordova, E. G. (2014). Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. *Cochrane Database of Systematic Reviews*, 3, CD009893.
doi:<http://dx.doi.org/10.1002/14651858.CD009893.pub2>
- Skaistis, J., & Tagami, T. (2015). Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. *PLoS One*, 10(9), e0137444.
- Steinberg, B. A. (2014). Systematic review and meta-analysis: Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation. *Evidence-Based Medicine*, 19(5), 182. doi:<http://dx.doi.org/10.1136/ebmed-2014-110004>
- Vaz Carneiro, A., & Costa, J. (2014). [Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. *Cochrane Database Syst Rev*. 2014,3:CD009893]. *Acta Medica Portuguesa*, 27(2), 157-159.